Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance
Christina Guo(Peter MacCallum Cancer Centre), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Jane Goodall, Mahtab Rouhifard(Institute of Cancer Research), Ana Ferreira(Institute of Cancer Research), Karen E. Swales(Institute of Cancer Research), Reece Caldwell(Royal Marsden NHS Foundation Trust), Mona Parmar(Institute of Cancer Research), Wei Yuan(Shanghai Public Health Clinical Center), Bora Gürel(Institute of Cancer Research), Holly Tovey(Institute of Cancer Research), Jesús Gil(MRC London Institute of Medical Sciences), Alison Turner(Institute of Cancer Research), Daniel Westaby(Royal Marsden NHS Foundation Trust), Antje Neeb(Institute of Cancer Research), Christina Yap(Institute of Cancer Research), Bianca Calì(Institute of Oncology Research), Caterina Aversa(Royal Marsden NHS Foundation Trust), Ursula Vogl(Institute of Oncology Research), Mateus Crespo(Institute of Cancer Research), Ilaria Colombo(Ente Ospedaliero Cantonale), Shaun Decordova(Institute of Cancer Research), Denisa Bogdan(Institute of Cancer Research), Anastasios Stathis(Princess Margaret Cancer Centre), Jan Rekowski(Institute of Cancer Research), Toby Prout(Institute of Cancer Research), Nina Tunariu(Leicester Royal Infirmary), David Waugh(University of South Australia), Florence I. Raynaud(Institute of Cancer Research), Ruth Ruddle(Institute of Cancer Research), Ruth Matthews(Institute of Cancer Research), Lewis Gallagher(Institute of Cancer Research), Ruth Riisnaes(Institute of Cancer Research), Penny Flohr(Royal Marsden NHS Foundation Trust), Adam Sharp(Institute of Cancer Research), Crescens Tiu(Royal Marsden NHS Foundation Trust), Andrea Alimonti(Veneto Institute of Molecular Medicine), Hannah Badham(Institute of Cancer Research), Suzanne Carreira(Institute of Cancer Research), Jason Malia(Institute of Cancer Research), Maria D. Fenor de la Maza(Royal Marsden NHS Foundation Trust), Alec Paschalis(Royal Marsden NHS Foundation Trust), Ines Figueiredo(Institute of Cancer Research), Khobe Chandran(Royal Marsden NHS Foundation Trust), Anna Schlag(Institute of Cancer Research), Juliet Carmichael(Royal Marsden NHS Foundation Trust), Cláudia Bertan(Institute of Cancer Research), Suneil Jain(Queen's University Belfast), George Seed(Institute of Cancer Research)
Cited by 119
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k